文献速递食管胃疾病与幽门螺杆菌

欧洲幽门螺杆菌管理登记研究5000例患者中的经验性二线治疗

Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-12-23

该研究基于欧洲幽门螺杆菌管理登记(Hp-EuReg)的多中心前瞻性非干预数据,纳入5055例既往接受过根除治疗的成人感染者,评估经验性二线治疗的有效性与安全性。含阿莫西林和左氧氟沙星的三联疗法最常用(33%),总体有效率按改良意向性治疗分析为82%、按符合方案人群为83%;不良事件发生率为28%,多数为轻度,3例(0.3%)出现需住院的严重不良事件。

要点

  • 经验性二线治疗总体有效率按改良意向性治疗分析为82%,按符合方案人群为83%。
  • 含莫西沙星三联或含铋左氧氟沙星四联在克拉霉素一线治疗失败后可达>90%根除率。
  • 3-in-1单胶囊或左氧氟沙星-铋四联的根除率不受质子泵抑制剂剂量、疗程或既往一线治疗影响。

核心结论

  • 含14天喹诺酮三联、14天左氧氟沙星-铋四联、14天四环素-铋经典四联及10天铋四联(单胶囊)的经验性二线方案可提供最佳有效性,但许多其他评估的二线治疗根除率低。

研究设计与样本

  • 国际、多中心、前瞻性、非干预性登记研究,评估欧洲消化科医生对幽门螺杆菌管理的决策与结局。
  • 所有既往接受过根除治疗的成人感染者通过西班牙消化病学会-研究电子数据采集系统登记至2021年2月。
  • 排除对青霉素过敏者及接受药敏指导治疗者,并进行数据监测以确保数据质量。
  • 共5055例患者接受经验性二线治疗。

主要发现

  • 含阿莫西林和左氧氟沙星的三联疗法最常用(33%)。
  • 总体有效率按改良意向性治疗分析为82%,按符合方案人群为83%。
  • 一线含克拉霉素治疗失败后,含莫西沙星三联或含铋左氧氟沙星四联可达>90%的根除率。
  • 含左氧氟沙星或莫西沙星三联及左氧氟沙星-铋四联采用14天疗程和高剂量质子泵抑制剂时治愈率优化。
  • 3-in-1单胶囊或左氧氟沙星-铋四联的根除率可靠,不受质子泵抑制剂剂量、疗程或既往一线治疗影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: After a first Helicobacter pylori eradication attempt, approximately 20% of patients will remain infected. The aim of the current study was to assess the effectiveness and safety of second-line empiric treatment in Europe. METHODS: This international, multicenter, prospective, non-interventional registry aimed to evaluate the decisions and outcomes of H pylori management by European gastroenterologists. All infected adult cases with a previous eradication treatment attempt were registered with the Spanish Association of Gastroenterology-Research Electronic Data Capture until February 2021. Patients allergic to penicillin and those who received susceptibility-guided therapy were excluded. Data monitoring was performed to ensure data quality. RESULTS: Overall, 5055 patients received empiric second-line treatment. Triple therapy with amoxicillin and levofloxacin was prescribed most commonly (33%). The overall effectiveness was 82% by modified intention-to-treat analysis and 83% in the per-protocol population. After failure of first-line clarithromycin-containing treatment, optimal eradication (>90%) was obtained with moxifloxacin-containing triple therapy or levofloxacin-containing quadruple therapy (with bismuth). In patients receiving triple therapy containing levofloxacin or moxifloxacin, and levofloxacin-bismuth quadruple treatment, cure rates were optimized with 14-day regimens using high doses of proton pump inhibitors. However, 3-in-1 single capsule or levofloxacin-bismuth quadruple therapy produced reliable eradication rates regardless of proton pump inhibitor dose, duration of therapy, or previous first-line treatment. The overall incidence of adverse events was 28%, and most (85%) were mild. Three patients developed serious adverse events (0.3%) requiring hospitalization. CONCLUSIONS: Empiric second-line regimens including 14-day quinolone triple therapies, 14-day levofloxacin-bismuth quadruple therapy, 14-day tetracycline-bismuth classic quadruple therapy, and 10-day bismuth quadruple therapy (as a single capsule) provided optimal effectiveness. However, many other second-line treatments evaluated reported low eradication rates. ClincialTrials.gov number: NCT02328131.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Nyssen OP, Vaira D, Pérez Aísa Á, et al. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clin Gastroenterol Hepatol. 2021. PMID: 34954341. doi:10.1016/j.cgh.2021.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。